Companion Diagnostics is as a bio-scientific strategy intended for the evaluation of the patient to check whether tolerant reacts to a particular medicinal treatment or not. Companion diagnostics are utilized to figure out which patients are profited by a specific kind of prescription or which treatments are most appropriate for patients with certain ailments
The global Companion diagnostics market was valued at $ XX Mn in 2018 and is forecast to grow at a strong XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by owing to the rising associations and coordinated efforts for companion diagnostics test development and growing cancer incidence globally. However, undefined repayment scenarios in different regions are restraining market growth. Rising demand for next-generation sequencing is providing ample opportunities for the market
Companion diagnostics Market depending on the indication, Neurology is expected to account for the largest share of the healthcare Companion diagnostics market. Neurology is a part of medicine managing issue of the nervous system. Neurology system manages the diagnosis and treatment of all classes of conditions and illness including the central and peripheral nervous systems, including their blood vessels, all effector tissue, such as muscle and coverings
The global Companion diagnostics in the Healthcare market is segmented on the basis of indication, technology, product & service, end-user, and region
Based on the Indication: Oncology, Neurology, Infectious Diseases, and Other Indications
Based on the Technology: Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, Polymerase Chain Reaction, and Other Technologies
Based on the Product & Service: Software & Services and Assay Kits and Reagents
Based on the End-user: Reference laboratories, pharmaceutical, and biopharmaceutical companies, hospitals and other end users
Based on the region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market, followed by Europe due. The large share of North America in this market is attributed high healthcare technology implementation rates and expanding interest for customized drug, the market for diagnostics in the United States is required to enroll a considerable development rate amid the estimate forecast period
The key players of the Global Companion diagnostics in Healthcare market include Almac Group, Novartis AG, Hologic Inc., Sysmex Corporation, Arup Laboratories Inc., Myriad Genetics, Inc., Illumina, Inc., Biomérieux SA, Abbott Laboratories, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, Inc., F. Hoffmann-La Roche AG and Others
Report Description: The report covers in-depth analysis of the Global Companion Diagnostics Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Indication (Oncology, Neurology, Infectious Diseases, and Other Indications) by End User (Reference Laboratories, Pharmaceutical, and Biopharmaceutical Companies and Other End Users). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations
The report includes in-depth company profiles of key players in Global Companion diagnostics in the Healthcare Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.